Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ValiRx plc ( (GB:VAL) ) has issued an announcement.
ValiRx’s subsidiary, Inaphaea BioLabs, has extended its agreement with Dominion Biotech to explore repurposing FDA-approved drugs for cancer applications. This collaboration aims to unlock potential new cancer treatments by analyzing existing data sets, potentially accelerating development timelines and offering new options for patients. Both companies will share costs and revenues from any resulting patents and commercialized assets, enhancing ValiRx’s operational impact and industry positioning.
More about ValiRx plc
ValiRx is a life sciences company focused on early-stage cancer therapeutics and women’s health. It accelerates the translation of innovative science into impactful medicines, providing a framework for rapid clinical development. ValiRx selects and incubates promising drug candidates, guiding them from pre-clinical studies to investor-ready assets, and collaborates with diverse experts to streamline the drug development process. The company is listed on the AIM Market of the London Stock Exchange under the ticker symbol VAL.
Average Trading Volume: 2,348,647
Technical Sentiment Signal: Sell
Current Market Cap: £2.06M
Learn more about VAL stock on TipRanks’ Stock Analysis page.